B Ahren
Overview
Explore the profile of B Ahren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
583
Citations
6412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ji L, Ahmann A, Ahren B, Capehorn M, Hu P, Lingvay I, et al.
Diabetes Obes Metab
. 2023 Oct;
26(1):233-241.
PMID: 37822270
Aim: To compare the proportion of participants with type 2 diabetes (T2D) treated with once-weekly (OW) subcutaneous (SC) semaglutide versus comparators who achieved a composite metabolic endpoint. Materials And Methods:...
2.
Ahmadi S, Filipsson K, Dimenas H, Isaksson S, Imberg H, Sjoberg S, et al.
Obes Sci Pract
. 2019 Apr;
5(2):130-140.
PMID: 31019730
Aim: Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated...
3.
Ahren B
Diabetes Metab
. 2016 Jan;
41(6 Suppl 1):6S3-6S8.
PMID: 26774018
Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over...
4.
Alsalim W, Tura A, Pacini G, Omar B, Bizzotto R, Mari A, et al.
Diabetes Obes Metab
. 2015 Sep;
18(1):24-33.
PMID: 26354383
Aims: To study the integrative impact of macronutrients on postprandial glycaemia, β-cell function, glucagon and incretin hormones in humans. Methods: Macronutrients were ingested alone (glucose 330 kcal, protein 110 kcal...
5.
Thorens B, Accili D, Ahren B, Cerasi E, Seino S, Boitard C
Diabetes Obes Metab
. 2015 Sep;
17 Suppl 1:3-5.
PMID: 26332961
No abstract available.
6.
Accili D, Ahren B, Boitard C, Seino S, Thorens B, Cerasi E
Diabetes Obes Metab
. 2014 Sep;
16 Suppl 1:1-3.
PMID: 25200289
No abstract available.
7.
Omar B, Liehua L, Yamada Y, Seino Y, Marchetti P, Ahren B
Diabetologia
. 2014 Jun;
57(9):1876-83.
PMID: 24939431
Aims/hypothesis: Inhibition of the enzyme dipeptidyl peptidase 4 (DPP-4), which cleaves and inactivates glucagon-like peptide 1 (GLP-1), is a glucose-lowering strategy in type 2 diabetes. Since DPP-4 is a ubiquitously...
8.
Ahren B, Gautier J, Berria R, Stager W, Aronson R, Bailey C
Diabetes Obes Metab
. 2014 Mar;
16(9):861-8.
PMID: 24641271
Aim: Glucagon-like peptide-1 (GLP-1) receptor agonists improve islet function and delay gastric emptying in patients with type 2 diabetes mellitus (T2DM). This meta-analysis aimed to investigate the effects of the...
9.
Farngren J, Persson M, Schweizer A, Foley J, Ahren B
Diabetes Obes Metab
. 2014 Mar;
16(9):812-8.
PMID: 24612221
Aims: To determine the effects of dipeptidyl peptidase-4 (DPP-4) inhibition on glucagon dynamics in patients with insulin-treated type 2 diabetes (T2D). Methods: The study was a single-centre, double-blind, randomized, placebo...
10.
Ahren B, Accili D, Boitard C, Cerasi E, Thorens B, Seino S
Diabetes Obes Metab
. 2013 Sep;
15 Suppl 3:4-9.
PMID: 24003915
No abstract available.